undamentalytics Newsletter
Sign in

Fortress Biotech, Inc. revenue

Fortress Biotech, Inc.'s revenue was $63.3m in fiscal 2025, up 9.7% on the year before. Since fiscal 2015 ($863,000) it has grown at a compound 53.6% a year. Over the last twelve months it was $68.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00116188273746697685586368
Growth on the year before———+>999%+>999%−85.7%+36.3%+24.5%+50.9%+10.1%+11.6%−31.8%+9.7%—
Gross profit————184212631374562374245

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Journey $61.2M 97.8% ▲ 11.1%
Avenue Therapeutics Inc $1.4M 2.2% —
Products and services
Line of business Revenue YoY
Qbrexza $25M ▼ 0.4%
Emrosi $14.7M —
Accutane $12.9M ▼ 33.6%
Foam Franchise Products $5.9M ▼ 11.9%
Other Legacy Product Revenue $2.7M ▼ 30.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Fortress Biotech, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Fortress Biotech, Inc. $68.5m 15.5% 3.0%
Recursion Pharmaceuticals, Inc. $68.2m 56.2% 12.9%
Cytokinetics Inc $67.7m -21.1% 89.5%
Abcellera Biologics Inc. $66.2m 101.3% -23.0%
Wave Life Sciences, Inc. $70.9m 202.3% 20.7%
Viridian Therapeutics, Inc.\de $71.1m 23220.3% 264.4%

Compare with peers

Head to head: FBIO vs RXRXCYTK vs FBIOABCL vs FBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fortress Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fortress Biotech, Inc.